UB-VV400 with rapamycin for B-cell lymphoma that has returned or not responded
Tests UB-VV400 with rapamycin in adults with relapsed or treatment-resistant B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Key facts
- Where
- Irvine and Nashville, United StatesSee the 2 sites
- Phase
- Phase 1/2
Where in United States
- City of HopeIrvine, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Umoja Biopharma
- Trial code
- NCT07735533
- Record updated
- 10 November 2026
- Original description
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).Read full original descriptionShow less
A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Inclusion: 18 years or older; Provides voluntary written informed consent; Relapsed or refractory large B-cell lymphoma (LBCL); Measurable disease according to Lugano 2014 criteria; Confirmed CD22 expression; No serious concomitant diseases or active/uncontrolled infections; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Adequate organ function.
Exclusion: Currently receiving treatment in another interventional clinical trial; History of or active human immunodeficiency virus (HIV); Active or chronic hepatitis B, or active hepatitis C; Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease; Ongoing CNS disease that would preclude neurologic assessment; Uncontrolled angina or other acute heart disease; Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor [TCR] fusion constructs, TCR T cells, and CAR T cells); Women who are pregnant or breastfeeding; Current isolated central nervous system (CNS) involvement.